<DOC>
<DOCNO>EP-0618209</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Pyridothiadiazines, processes for their preparation and pharmaceutical compositions containing them
</INVENTION-TITLE>
<CLASSIFICATIONS>C07D51300	C07D51304	A61P2520	A61P2526	A61K3154	A61P2500	A61P2528	A61P2524	A61P2500	A61K3154	A61P2518	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>C07D	C07D	A61P	A61P	A61K	A61P	A61P	A61P	A61P	A61K	A61P	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>C07D513	C07D513	A61P25	A61P25	A61K31	A61P25	A61P25	A61P25	A61P25	A61K31	A61P25	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
The invention relates to the compounds of formula (I): 
<
IMAGE
>
  in which A, R1, R2 and R4 are as defined in the description. Medicaments.
</ABSTRACT>
<APPLICANTS>
</APPLICANTS>
<INVENTORS>
</INVENTORS>
<CLAIMS>
Compounds of formula (I):


in which:

R
1
 represents a group selected from:

hydrogen,
R
3
, with R
3
 representing a radical selected from lower alkyl, lower alkenyl and
lower alkynyl, R
3
 being unsubstituted or substituted,
cycloalkyl,
substituted cycloalkyl,
cycloalkyl-lower alkyl,
substituted cycloalkyl-lower alkyl,
lower acyl,
lower alkoxycarbonyl,
arylcarbonyl that is unsubstituted or substituted on the aryl ring, and
aryloxycarbonyl that is unsubstituted or substituted on the aryl ring,

or R
1
 forms a double bond between atoms 3 and 4 of the thiadiazine ring present in
formula (I);
R
2
 represents a group selected from:

hydrogen,
R
10
, with R
10
 having the same definition as R
3
 above, R
10
 being unsubstituted or
substituted,
R
11
, with R
11
 representing a group selected from cycloalkyl, cycloalkyl-lower alkyl,
bicycloalkyl and bicycloalkyl-lower alkyl, R
11
 being unsubstituted or substituted,
-O-R
10
, wherein R
10
 is as defined above, 
thioxo,
-S-R
12
, wherein R
12
 represents a lower alkyl radical, R
12
 being unsubstituted or
substituted,
aryl,
substituted aryl, and


wherein R
8
 and R
9
 each independently of the other represents a
radical selected from:
hydrogen,
lower alkyl,
cycloalkyl,
cycloalkyl-lower alkyl, and
a heterocycle R
13
 selected from pyrrolidine, piperidine, piperazine, morpholine and
thiomorpholine,
or R
8
 and R
9
 together with the nitrogen atom carrying them form a heterocycle R
13

as defined above;
R
4
 represents a group selected from:

hydrogen,
R
14
, with R
14
 having the same definition as R
3
 above, R
14
 being unsubstituted or
substituted,
cycloalkyl,
aryl,
substituted aryl,
lower acyl,
lower alkoxycarbonyl,
arylcarbonyl that is unsubstituted or substituted on the aryl ring, and
aryloxycarbonyl that is unsubstituted or substituted on the aryl ring,

or R
4
 forms a double bond between atoms 2 and 3 of the thiadiazine ring present in
formula (I);
A with the two carbon atoms carrying it forms a pyridine ring selected from the
groups A
1
, A
2
, A
3
 and A
4
: 


in which R
5
, R
6
 and R
7
 each independently of the others represents a radical
selected from: hydrogen, halogen, lower alkyl, hydroxy, thiol, lower alkoxy, lower

alkylthio, trifluoromethyl, carboxy, lower acyl, aryl, aryl-lower alkyl, amino, lower
alkylamino and di-lower alkylamino,

with the proviso that when A represents an unsubstituted group of the formula A
1
,
R
2
 represents a hydrogen atom, an amino radical or a methyl radical, and R
5
, R
6

and R
7
 simultaneously represent hydrogen atoms, then R
1
 may not be a hydrogen
atom or a methyl radical,

with the proviso that the compound of formula (I) may not be 4H-pyrido[4,3-e]-1,2,4-thiadiazine

1,1-dioxide,

wherein, unless indicated to the contrary:

"lower alkyl", "lower alkoxy", "lower acyl" and "lower alkylthio" denote linear or
branched groups having from 1 to 6 carbon atoms,
"lower alkenyl" denotes a linear or branched group having from 2 to 6 carbon
atoms containing 1 or 2 double bonds,
"lower alkynyl" denotes a linear or branched group having from 2 to 6 carbon
atoms containing 1 or 2 triple bonds,
"cycloalkyl" denotes a cyclic group having from 3 to 8 carbon atoms,
"bicycloalkyl" denotes a bicyclic group having from 6 to 12 carbon atoms, 
"aryl" denotes phenyl or naphthyl,
"substituted" associated with the groups R
3
, R
10
 and R
14
 means that those groups
so qualified are substituted by one or more radicals selected from halogen, hydroxy

and lower alkoxy,
"substituted" associated with the groups "cycloalkyl", "cycloalkylalkyl" and R
11

means that those groups so qualified are substituted by one or more radicals or
groups selected from oxo, hydroxy, lower alkyl and lower alkoxy,
"substituted" associated with the aryl group means that that group so qualified is
substituted by one or more radicals selected from halogen, hydroxy, lower alkyl,

lower alkoxy and trifluoromethyl,
their optical isomers,
and addition salts thereof with a pharmaceutically acceptable acid or base.
Compound according to claim 1 which is 4-isopropyl-2,3-dihydro-4H-pyrido-[4,3-e][1,2,4]
thiadiazine
1,1-dioxide.
Compound according to claim 1 which is 3,4-dimethyl-4H-pyrido[4,3-e][1,2,4]
-thiadiazine
1,1-dioxide.
Compound according to claim 1 which is 4-methyl-2,3-dihydro-4H-pyrido[4,3-e]-[1,2,4]
thiadiazine
1,1-dioxide.
Compound according to claim 1 which is 2,3-dimethyl-2,3-dihydro-4H-pyrido-[4,3-e][1,2,4]
thiadiazine
1,1-dioxide.
Compound according to claim 1 which is 4-methyl-2,3-dihydro-4H-pyrido[3,2-e]-[1,2,4]
thiadiazine
1,1-dioxide.
Compound according to claim 1 which is 4-ethyl-2,3-dihydro-4H-pyrido[3,2-e]-[1,2,4]
thiadiazine
1,1-dioxide.
Process for the preparation of compounds of formula (I) according to claim 1,
characterised in that a compound of formula (II): 



in which R
1
, R
4
 and A are as defined in claim 1,

is reacted

a) either with a compound of formula (III):


in which R
a
 represents an R
10
, R
11
, aryl or substituted aryl group, as defined in
claim 1,

or, while heating, with a compound of formula (IV):


to give a compound of formula (I/a):


in which R
1
, R
4
, R
a
 and A are as defined above, which is a particular case of the
compounds of formula (I) in which R
2
 represents a group R
a
,
 
or with paraformaldehyde, ethyl orthoformate or a formic acid/acetic acid mixed

anhydride, to give a compound of formula (I/b):


in which R
1
, R
4
 and A are as defined above, which is a particular case of the
compounds of formula (I) in which R
2
 represents a hydrogen atom,

or alternatively
b) with urea to yield a compound of formula (V):


in which R
1
, R
4
 and A are as described above,

which is then:

converted into a salt and then reacted with a compound of formula (VI):

R
10
-Hal

in which R
10
 is as defined in claim 1 and Hal represents a halogen atom,
to give a compound of formula (I/c):


 
in which R
1
, R
4
, R
10
 and A are as defined above, which is a particular case of the
compounds of formula (I) in which R
2
 represents a group -O-R
10
,
or subjected to a thionating agent to give a compound of formula (I/d):


in which R
1
, R
4
 and A are as defined above, which is a particular case of the
compounds of formula (I) in which R
2
 represents a thioxo group,

which compound of formula (I/d) is reacted with a compound of formula (VI):

Hal'-R
12

in which R
12
 is as defined in claim 1 and Hal' represents a halogen atom,
to give a compound of formula (I/e):



in which R
1
, R
4
, R
12
 and A are as defined above, which is a particular case of the
compounds of formula (I) in which R
2
 represents an alkylthio group,

which compound of formula (I/e) may then be subjected to an amine of
formula (VII): 



in which R
8
 and R
9
 are as defined in claim 1,

to give a compound of formula (I/F):


in which R
1
, R
4
, R
8
, R
9
 and A are as defined above, which is a particular case of the
compounds of formula (I) in which R
2
 represents a group -NR
8
R
9
,

the compounds of formulae (I/a) to (I/f) forming the totality of the compounds of
formula (I),

it being understood that the compounds of formulae (I/a), (I/b), (I/c), (I/e) and (I/f)
may optionally be reduced selectively in order to obtain the corresponding

compounds of formula (I) wherein the bond between atoms 2 and 3, or between
atoms 3 and 4, of the thiadiazine ring is saturated,

which compounds of formula (I) may be:

purified by one or more purification methods selected from crystallisation,
chromatography on a silica column, extraction, filtration, and passage over charcoal

or resin,
separated, in pure form or in the form of a mixture, into their possible optical
isomers,
and converted into a salt by means of a pharmaceutically acceptable acid or base.
Process for the preparation of compounds of formula (I/a), a particular case of the
compounds of formula (I) according to claim 1: 



in which R
1
, R
4
 and A are as defined in claim 1 and R
15
 represents a group R
10
 or
R
11
 as defined in claim 1,

characterised in that:

a compound of formula (II/a):


in which R
1
, R
4
, R
15
 and A are as defined above,

is subjected to a cyclising agent in order to obtain the corresponding compound of
formula (I/a),

which compounds of formula (I/a) so obtained may be:

purified by one or more purification methods selected from crystallisation,
chromatography on a silica column, extraction, filtration, and passage over charcoal

or resin,
separated, in pure form or in the form of a mixture, into their possible optical
isomers,
and converted into a salt by means of a pharmaceutically acceptable acid or base.
Process for the preparation of compounds of formula (I/g), a particular case of
the compounds of formula (I) according to claim 1: 



in which R
4
, R
8
, R
9
 and A are as defined in claim 1, which are a particular case of
the compounds of formula (I) in which R
2
 represents a group -NR
8
R
9
 and R
1

represents a hydrogen atom,

characterised in that:

either a compound of formula (II/b):


in which R
4
, R
8
, R
9
 and A are as defined above and Hal" represents a halogen atom,
is reacted, while heating, in a basic medium,
or a compound of formula (II):


in which R
1
, R
4
 and A are as defined above,

is reacted with a compound of formula (VIII):

 
in which R
8
 and R
9
 are as defined above,

in order to obtain the corresponding compound of formula (I/g),

which compounds of formula (I/g) may be:
purified by one or more purification methods selected from crystallisation,
chromatography on a silica column, extraction, filtration, and passage over charcoal

or resin,
separated, in pure form or in the form of a mixture, into their possible optical
isomers,
and converted into a salt by means of a pharmaceutically acceptable acid or base.
Process for the preparation of compounds of formula (I/h), a particular case of
the compounds of formula (I) according to claim 1:



in which R
1
, R
4
 and A are as defined in claim 1, with the proviso that at least one of
the substituents R
1
 and R
4
 is other than a hydrogen atom,

characterised in that:

a compound of formula (I/i):


in which R
2
, R
4
 and A are as defined above,

is reacted with a compound of formula (XI): 

R
1
'-X

in which R
1
' has the same meanings as R
1
 as defined in claim 1, with the exception
of hydrogen, and X represents a leaving group,

and/or, when R
4
 represents a hydrogen atom, with a compound of formula (XII):

R
4
'-X'

in which R
4
' has the same meanings as R
4
 as defined in claim 1, with the exception
of hydrogen, and X' represents a leaving group,

it being possible for the compounds of formula (I/h) so obtained to be:

purified by one or more purification methods selected from crystallisation,
chromatography on a silica column, extraction, filtration, and passage over charcoal

or resin,
separated, in pure form or in the form of a mixture, into their possible optical
isomers,
and converted into a salt by means of a pharmaceutically acceptable acid or base.
Pharmaceutical composition comprising a compound according to claim 1 or a
salt thereof with a pharmaceutically acceptable acid or base, in combination with

one or more pharmaceutically acceptable excipients or carriers.
Pharmaceutical composition according to claim 12 comprising a compound
according to claim 1 or a salt thereof with a pharmaceutically acceptable acid or

base, for use in the treatment and prevention of pathologies associated with dysfunctioning
of glutamatergic neurotransmission.
Pharmaceutical composition according to claim 13 for use in the treatment and
prevention of mnemocognitive disorders associated with age and with anxiety or

depressive syndromes, of progressive neurodegenerative diseases, of Alzheimer's
disease, of Pick's disease, of Huntington's chorea, of schizophrenia, of the after-effects

of acute neurodegenerative diseases, of the after-effects of ischaemia, and
of the after-effects of epilepsy.
</CLAIMS>
</TEXT>
</DOC>
